



Universiteit
Leiden
The Netherlands

Quantitative comparison of different iron forms in the temporal cortex of Alzheimer patients and control subjects

Bulk, M.; Weerd, L. van der; Breimer, W.; Lebedev, N.; Webb, A.; Goeman, J.J.; ... ; Bossoni, L.

Citation

Bulk, M., Weerd, L. van der, Breimer, W., Lebedev, N., Webb, A., Goeman, J. J., ... Bossoni, L. (2018). Quantitative comparison of different iron forms in the temporal cortex of Alzheimer patients and control subjects. *Scientific Reports*, 8, 6898.
doi:10.1038/s41598-018-25021-7

Version: Not Applicable (or Unknown)
License: [Leiden University Non-exclusive license](#)
Downloaded from: <https://hdl.handle.net/1887/70910>

Note: To cite this publication please use the final published version (if applicable).

SCIENTIFIC REPORTS



OPEN

Quantitative comparison of different iron forms in the temporal cortex of Alzheimer patients and control subjects

Marjolein Bulk^{1,2,3}, Louise van der Weerd^{1,2}, Wico Breimer⁴, Nikita Lebedev⁴, Andrew Webb¹, Jelle J. Goeman⁵, Roberta J. Ward⁶, Martina Huber⁴, Tjerk H. Oosterkamp⁴ & Lucia Bossoni^{1,4}

We present a quantitative study of different molecular iron forms found in the temporal cortex of Alzheimer (AD) patients. Applying the methodology we developed in our previous work, we quantify the concentrations of non-heme Fe(III) by Electron Paramagnetic Resonance (EPR), magnetite/maghemite and ferrihydrite by SQUID magnetometry, together with the MRI transverse relaxation rate (R_2^*), to obtain a systematic view of molecular iron in the temporal cortex. Significantly higher values of R_2^* , a larger concentration of ferrihydrite, and a larger magnetic moment of magnetite/maghemite particles are found in the brain of AD patients. Moreover, we found correlations between the concentration of the iron detected by EPR, the concentration of the ferrihydrite mineral and the average iron loading of ferritin. We discuss these findings in the framework of iron dis-homeostasis, which has been proposed to occur in the brain of AD patients.

Iron is an essential component of many enzymes and proteins that participate in a variety of biological functions in the brain, such as neurotransmitter synthesis and myelination of neurons¹. Increases in the iron content of specific brain regions were identified in many neurodegenerative diseases, e.g. Alzheimer's Disease (AD), Parkinson's Disease, and Friederich Ataxia²⁻⁶. In AD, which is clinically characterised by progressive dementia, increased iron content in the temporal, parietal and frontal lobes has been reported^{7,8}. In the presence of the pathological hallmarks of AD, iron is accumulated within and around the amyloid-beta plaques (A β) and neurofibrillary tangles^{3,9}, mostly as ferrihydrite inside ferritin, hemosiderin, and magnetite.

The co-localization of iron with A β has been proposed to constitute a major source of toxicity. Indeed, *in vitro*, A β has been shown to convert ferric iron (Fe(III)) to ferrous (Fe(II)) iron^{10,11}, which can act as a catalyst for the Fenton reaction to generate toxic free radicals, which in turn result in oxidative stress.

Mineralized forms of iron, other than ferrihydrite, are found inside^{12,13} and outside ferritin^{14,15}. For example, it has been shown that magnetite and wüstite are both present in the AD brain¹⁵. This is of importance as such species possess Fe(II), which is associated with toxicity. Although these nanoparticles may be present in low concentrations¹⁶, if they are larger than 40–50 nm in diameter, they carry a permanent magnetic moment at room temperature^{14,15,17}, which can significantly affect the proton Nuclear Magnetic Resonance Imaging (MRI) signal, thus allowing *indirect* imaging of iron¹⁸⁻²⁰.

The magnetic moment of iron/iron nanoparticles dephases the proton spins of close-by diffusing water molecules, leading to the shortening of the endogenous spin-spin relaxation times (T_2 and T_2^*)^{18,21-23}. Therefore, local iron accumulation is observed as hypointense areas on T_2 and T_2^* -weighted multi-echo MRI sequences. *In vivo* and post-mortem MRI have shown that in AD, cortical iron can be visualized as bands or foci of signal loss^{24,25}. In

¹Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

²Department of Human Genetics, Leiden University Medical Center, Einthovenweg 20, 2333 ZC, Leiden, The Netherlands. ³Percuro's B. V, Leiden, The Netherlands. ⁴Huygens-Kamerlingh Onnes Laboratory, Leiden University, PO Box 9504, 2300 RA, Leiden, The Netherlands. ⁵Department of Statistics, Leiden University Medical Center, Einthovenweg 20, 2333 ZC, Leiden, The Netherlands. ⁶Imperial College London, Hammersmith Hospital Campus, Du Cane Rd., London, W12 0NN, England. Correspondence and requests for materials should be addressed to L.B. (email: l.bossoni@lumc.nl)

addition, elevated tissue ferritin levels are often associated with low values of T_2^* in AD patients^{26,27}. Susceptibility-weighted imaging (SWI)¹⁸ and quantitative susceptibility mapping (QSM)^{28,29} are methods based on the correspondence between measured phase and local magnetic field, and were employed to assess brain iron^{30,31}. However, the results from SWI analyses depend on the particular orientation, geometry and position of the dipolar field source, and both SWI and QSM do not differentiate between molecular forms of iron. Moreover, although a positive linear correlation between MRI relaxation times and tissue iron has been shown^{27,30,32–35}, most of the MRI studies refer to “iron” in very general terms, while only a few studies have investigated correlations between MRI relaxation times and specific molecular iron forms, mostly as ferritin-stored iron^{26,27,36}. Non-heme iron types are diverse and contribute differently to the MRI relaxation times, via their different magnetic moments³⁷. Indeed, there are many other potential confounding factors in using susceptibility for absolute iron quantification, for example, a lower cell water content, abrupt susceptibility changes¹⁸, changes in myelination^{36,38} and co-localization with A β ³⁹.

In order to provide a systematic and quantitative view of different molecular/mineral iron forms in brain tissue, we recently developed a combination of methods⁴⁰, by which we can quantify: (i) non-heme rhombic Fe(III); (ii) ferrihydrite ($\text{Fe}_2\text{O}_3 \cdot 0.5\text{H}_2\text{O}$) and (iii) magnetite/maghemite ($\text{Fe}_3\text{O}_4/\gamma\text{-Fe}_2\text{O}_3$). In contrast to previous studies, in which only one iron-oxide species was quantified, here we present a broad overview of iron forms obtained from a brain region where elevated iron concentration is found in AD. Furthermore, in this present work, we show how to derive the magnetic moment of magnetite and the iron loading of ferritin from magnetometry data. We apply the methodology described earlier⁴⁰ and we complement our set of techniques with MRI, which we performed on the same tissue sample used for the other experimental techniques.

In the present study, we have focussed on the middle temporal gyrus, since the temporal lobe is the most affected in terms of AD pathological hallmarks (A β and τ -tangles), and is the earliest cortical region to develop AD pathology. Additionally, there is evidence that both AD pathological hallmarks correlate with the amount of iron and myelin accumulation in the cortex⁴¹.

Finally, we applied our methodology to a substantially large number of samples (22 AD patients and 14 controls) and we found significant differences in the iron forms between AD and controls. Furthermore, we show correlations, which were previously undetected, among different iron forms.

Materials and Methods

All measurements and raw data analysis were carried out blind to diagnosis.

MRI experiments. Formalin-fixed tissue samples of the temporal middle gyrus were obtained from the Netherlands Brain Bank (NBB). Diagnosis of AD was confirmed by neuropathological examination in agreement with the guidelines of the ethics committee of the LUMC. Patient anonymity was strictly maintained. All tissue samples were handled in a coded fashion, according to Dutch national ethical guidelines (Code for Proper Secondary Use of Human Tissue, Dutch Federation of Medical Scientific Societies).

Before the Nuclear Magnetic Resonance Imaging (MRI) experiment, the tissue was washed in phosphate buffered saline (PBS) for 24 h, to remove residual formalin and partially restore the physiological proton relaxation times to those before fixation. Finally, the tissue was inserted into a plastic tube, immersed in a proton-free solution (fomblin), and kept in place by gauze.

MRI scans were performed on a 7T horizontal bore Bruker MRI system equipped with a 23 mm receiver coil and Paravision 5.1 imaging software (Bruker Biospin, Ettlingen, Germany).

High-spatial-resolution MRI scans were obtained with a three-dimensional T_2^* -weighted Multi-Gradient-Echo sequence. Repetition time $\text{TR} = 75$ ms, echo spacing $\text{TE} = 12.5, 23.3, 33.9$ and 44.6 ms, $100 \mu\text{m}$ isotropic resolution, flip angle = 15 degrees, 10 averages, 140×240 pixels. The complete imaging protocol had a total duration of 3.5 hours. The R_2^* rate was obtained after fitting the signal decay with the following expression:

$$y = Ae^{-TE \cdot R_2^*} \quad (1)$$

where A is a prefactor (See Supplementary Information for details on the quality of the fit). By inspecting the MRI scans of the samples from AD patients, a diffuse hypointense band, as described previously^{19,25}, was observed in the grey matter (see Fig. 1A). The region of interest (ROI) selection was guided by the MRI scan: the ROI included all cortical layers in an area where the diffuse hypointense band was observed. In the absence of the diffuse hypointense band, an ROI was selected including all cortical layers. The median R_2^* of this ROI was calculated for each patient sample. The median was chosen instead of the mean since it was more stable with respect to the ROI selection. Analysis of the MRI data was performed with Matlab 2016.

EPR experiments. A section of approximately 10–20 mg was dissected from the brain tissue with a ceramic scalpel, and prepared for the Electron Paramagnetic Resonance (EPR) study. Material from the same anatomical region was taken from the control subjects, for comparison. The tissue section was chosen to colocalize with the selected ROI on the MRI scan. EPR was performed with a 9 GHz spectrometer, at 12 K, according to the method presented earlier⁴⁰. The continuous wave (cw) EPR measurements were performed using an ELEXSYS E680 spectrometer (Bruker, Rheinstetten, Germany) equipped with a rectangular cavity. The microwave frequency was 9.4859 GHz, modulation frequency 100 kHz, power attenuation 20 dB, receiver gain 60 dB and modulation amplitude 6 G_{pp}. The accumulation time was 20 min. per spectrum. The concentration of Fe(III) (Fig. 1B) was determined for each patient by taking the second integral of the simulated signal, and by comparing it to the second integral of the reference sample (Fe-EDTA) of known concentration. All raw data with simulations are shown in the Supplementary Information. Data fitting to the spin Hamiltonian was performed with the EasySpin toolbox⁴². The spin Hamiltonian used for the fitting was typical for Fe(III), in the high-spin state:




Figure 1. Example of raw data obtained from this study. Panel A shows the MRI scan (third echo of the Multi-Gradient-Echo scan). Some dark bands are observable in the grey matter, and indicated by white arrows. Panel B shows the smoothed EPR spectrum obtained from the same subject. Panel C illustrates the IRM data measured with the SQUID magnetometer at 100 K (red curve), showing the presence of magnetite/maghemite, and 5 K (blue curve), attributed to the presence of ferritin.

$$H = g\mu_B(\mathbf{B} \cdot \mathbf{S}) + D\left(S_z^2 - \frac{S(S+1)}{3}\right) + E(S_x^2 - S_y^2) \quad (2)$$

where g is the Landé factor, μ_B the Bohr magneton, \mathbf{B} is the applied field and \mathbf{S} the spin operator. The two final terms represent the zero-field splitting, where D is the axial splitting, and E the rhombic splitting. The EPR spectra were fitted with the following parameters: $S = 5/2$, $D = 20.96$ GHz, $E/D = 0.3324$, $g = [1.83, 1.998, 2.0151]$, $g\text{strain} = [0.574, 0.129, 0.0197]$. More details on the spin Hamiltonian can be found elsewhere⁴⁰.

SQUID experiments. Subsequent to the EPR experiments, an additional tissue sample containing only mostly grey matter adjacent to the tissue block used for MRI, was resected. This tissue sample was freeze-dried, pelleted, and studied by a Superconducting Quantum Interference Device (SQUID) magnetometer (MPMS). Isothermal Residual Magnetization (IRM) curves were measured at 100 K and 5 K⁴⁰. We note that SQUID magnetometry is very sensitive for measuring magnetic impurities diluted in a non-magnetic host. However, one needs to make sure that the sample holder does not contain any fast-saturating component and that the field is zero and stable on the time-scale of the measurement. In this study, a Reciprocating Sample Option (RSO) probe, with sensitivity of 1×10^{-8} emu at low field (i.e. 0–2.5 T) was used. Despite the high sensitivity of the RSO, a few samples showed low signal-to-noise ratio (SNR) at 100 K. Those data were discarded from the analysis: we chose to set to zero the concentration of magnetite/maghemite of those samples whose 100 K-signal was close to the detection limit of the instrument, and the magnetic moment of these samples was discarded in the statistical analysis (see Results section). However, as shown in the Supplementary Information, many samples had a measurable signal and an SNR larger than 4. On the other hand, the 5 K data showed a signal that was much larger than the sensitivity of the instrument, for all samples.

The measured magnetic moment was divided by the dry mass of the sample, and the obtained IRM curve was fitted to the Langevin equation:

$$\text{IRM}[x] = M_s f [\coth(x) - 1/x] + B \quad (3)$$

where $x = \frac{\mu_p H}{k_B T}$, H is the magnetic field, μ_p is the average magnetic moment of the particles, k_B is the Boltzmann constant, T is the temperature, M_s is the saturation magnetization, f is the mass fraction of magnetic particles and B is a constant which takes into account residual fields. Both the 100 K and the 5 K data were fitted to the same Langevin equation (see Supplementary Information). IRM measured at 100 K was used to obtain the concentration of magnetite/maghemite nanoparticles and their magnetic moment, while the non-saturating data at 5 K (Fig. 1C) were used to derive the concentration of ferrihydrite^{37,43,44}. In the fit, the temperature and the saturation magnetization were fixed to the experimental condition and to the literature data, respectively. For magnetite (maghemite), different values of saturation magnetization are reported, ranging from 98 (76) emu/g for bulk material⁴⁵, to 72 emu/g for particles of size 30–40 nm⁴⁶, to lower values for 5 nm particles¹⁷. Magnetite/maghemite particles with a minimum particle-size of 25–35 nm have their magnetic moment blocked at approximately 100 K⁴⁰, therefore we used $M_s = 84$ emu/g, in the above equation as a reference value. As far as ferrihydrite is concerned, a saturation magnetization of $M_s = 0.62$ emu/g is typically accepted^{43,47}.

The fraction f of magnetic material, the magnetic moment μ_p , and the background constant B were obtained from the fit of each patient's curve (see Supplementary Information). For ferrihydrite, the magnetic moment is related to the number of iron atoms stored within the core of ferritin, also known as the loading factor (LF). According to Néel's theory of superparamagnetism, the relation between the two is given by⁴⁸:

$$\mu_p = 5.92 \mu_B \text{LF}^\alpha \quad (4)$$

where $\alpha = 0.5-0.6$, and $5.92 \mu_B$ corresponds to the ionic magnetic moment of Fe(III). Dividing LF by the maximum number of iron ions that ferritin can accommodate, i.e. 4500, we obtained the ferritin loading ratio (FLR), here expressed as a percentage, for clarity. Similarly, the magnetic moment of magnetite/maghemite is proportional to the volume of the particles. We will return to this concept in the following paragraphs.

Statistical analysis. Statistical analysis was performed using R-Studio (R version 3.3.2). The packages used were ggplot2⁴⁹, ggally⁵⁰, stats⁵¹, outliers⁵², corrplot⁵³ and ppcor⁵⁴. All data sets were tested for normality with the methods of visual inspection, q-q plot and normal Shapiro test. Outlier detection was done by visual inspection, q-q plot and Chi-square test. Data points were excluded only when the visual inspection and the formal tests agreed with each other. If required, normality was restored upon applying a \log_{10} -transformation: Fe(III) concentrations have been \log_{10} -transformed. $\text{Fe}_3\text{O}_4/\gamma\text{-Fe}_2\text{O}_3$ (magnetite/maghemite) data have been transformed with the following: $\log_{10}(x + C)$, where x is the particle concentration, and $C = 100$. Hypothesis testing (t-test) was performed on the transformed data. Differences in mean were considered significant when the p-value was smaller than 0.05. The variance of the distribution was also tested using the Brown-Forsythe Levene-type test, based on the absolute deviations from the median.

Spearman's correlation coefficients for all pairs of iron forms were calculated on non-transformed data. A formal comparison between the inter-group correlations coefficients was performed by Fisher-transforming the correlations coefficients (ρ) and then calculating their studentized difference as a basis for a two-tailed z-test. In more detail, we transformed ρ into z-scores, per group (i)⁵⁵:

$$zr_i = 1/2 \ln((1 + \rho_i)/(1 - \rho_i)). \quad (5)$$

Afterward, the difference in z-scores was calculated, with the following expression:

$$z_{diff} = \frac{zr_2 - zr_1}{\sqrt{1/(N_1 - 3) + 1/(N_2 - 3)}}, \quad (6)$$

where N_i is the number of individuals used for the calculation, and the index $i = 1, 2$ refers to the group (AD or control). This difference was used as a basis for a two-tailed z-test.

For those pairs of variables showing a significant correlation, a partial correlation test was carried out to exclude spurious correlations. In this last test, AD and control groups were pooled to increase the statistical power, in the case that the correlation comparison test was not significant.

Sample preparation. All details of sample preparation and handling are described in our previous work⁴⁰.

In this study, formalin-fixed material has been used. The effect of formalin fixation on the chemical state of iron is the subject of debate within the literature, with very different conclusions reached by different research groups⁵⁶. Although frozen brain material is probably the best starting material when it comes to the quantification of metals, working with frozen brain material is not a feasible option when a comparison among different techniques performed on the same piece of tissue is carried out. Most importantly, MRI cannot be easily done on frozen tissue, due to the very short T_2 values of frozen tissue as well as the long duration of high-resolution scans (typically of a few hours), which may affect the integrity of the tissue.

Finally, from a methodological point-of-view, it is worth noting that our results have been obtained without the need of chemical purification of the different iron forms, nor by performing any biochemical assay test, being based purely on the magnetic properties of the tissue.

Results

Table 1 reports the characteristics of the individuals and the concentration of the measured iron forms, as means and standard deviations. P-values obtained from the t-test (mean comparison) are also reported. No significant differences were found in age or gender between the AD and control group.

The value of R_2^* was significantly higher in the AD group vs. the control group ($p = 0.008$). Ferrihydrite concentration was significantly higher in the AD group ($p = 0.007$), while the ferritin loading ratio (FLR) was not significantly different between groups ($p = 0.362$). The concentration of magnetite/maghemite (note that the magnetite/maghemite will be named "magnetite" in the figures, for simplicity) nanoparticles was not different between the two groups ($p = 0.878$), while the average magnetic moment of the particles was larger in the AD group ($p = 0.002$). Finally, the Fe(III) concentration was not significantly different between groups ($p = 0.125$).

The extent to which the variance between the two groups is identical was also independently tested. We found that only the distribution of ferrihydrite concentration showed a significantly different variance between AD and control group ($p = 0.026$). The results of this test are reported in the Supplementary Information.

Subsequently, the individuals were stratified by their Braak Stage: control individuals with Braak Stage equal to or lower than 3 were grouped together. We found that those iron forms showing a significant inter-group difference in the mean, i.e. R_2^* values, ferrihydrite concentration and magnetite/maghemite magnetic moment, also showed a positive trend with increasing Braak Stage (Fig. 2), although no formal test was done due to the limited number of samples in each group.

We further carried out a correlation study to investigate associations among the measured iron forms, and between iron and R_2^* values. Figure 3 represents the correlation matrices (named correlogram hereafter) for all measured iron forms, in the form of ellipses, the eccentricity and intensity of which is equal to the Spearman's correlation coefficient between the variables reported on the axes.

Our initial findings indicate that some iron forms strongly correlate with each other. In particular, Fe(III) concentration positively associates with the FLR (Spearman's $\rho = 0.825$ for the AD patients, and 0.865 for the control subjects) and negatively with ferrihydrite concentration ($\rho = -0.629$ for the AD, and -0.908 for the control

	AD (n = 22)	Control (n = 14)	p-value mean test
<i>Characteristics</i>			
Male	8	4	0.248
Female	14	10	0.414
Mean age (range, yrs)	76.7 (43–96)	79.8 (64–91)	0.673
<i>Experimental Results</i>			
R_2^* (mean \pm sd, ms^{-1})	0.033 \pm 0.005	0.028 \pm 0.004	0.008
Fe(III) (mean \pm sd, $\mu\text{g/g}_{ww}$)	6.74 \pm 3.48	5.29 \pm 3.66	0.125
$\text{Fe}_3\text{O}_4/\gamma\text{-Fe}_2\text{O}_3$ (mean \pm sd, ng/g_{dw})	118.83 \pm 125.87	121.03 \pm 123.11	0.878
$\text{Fe}_2\text{O}_3 \cdot 0.5\text{H}_2\text{O}$ (mean \pm sd, $\mu\text{g/g}_{dw}$)	381.12 \pm 178.97	240.84 \pm 98.02	0.007

Table 1. Summary of sample characteristics and experimental results. A chi-square test was used to assess differences in gender between AD and control group. A Mann-Whitney U test was used to assess differences in age between AD and control group. Student's t-test was performed to test differences in the means of the measured iron concentrations. Statistical tests were repeated with and without the presence of the outliers, and the same conclusion about the significance of the test was reached. The index *dw* refers to dry weight, and *ww* refers to wet weight.

group). Additionally, ferrihydrite concentration correlates negatively with the FLR ($\rho = -0.729$ for the AD, and -0.935 for the control group), and the magnetite concentration associates positively with ferrihydrite concentration ($\rho = 0.474$) only for the AD group. The rest of the correlations were not significant.

When we compared the correlation coefficients between the two groups (AD vs. controls), we found that they were not significantly different, although the ferrihydrite-Fe(III) and the FLR-ferrihydrite pairs were associated with a rather small p-value (0.076 and 0.079, respectively) (see Supplementary Information, Table SII).

Since three variables were mutually correlated, we performed a partial correlation test to assess the correlation between two variables, while controlling for the effect of the third one. The results of the partial correlation are reported in Table 2. Note that during this test, the AD and control data were pooled, in the light of the results of the correlation comparison test.

The partial correlation test shows that the negative correlation found between Fe(III) and ferrihydrite may be spurious, and can be explained by the effect of the FLR variable.

Discussion

In this study, we seek to identify the differences in iron forms in the temporal cortex of Alzheimer patients and age- and gender-matched controls. A unique combination of techniques⁴⁰ enables us to differentiate these iron forms to a much larger degree than previously possible. One brain region affected by Alzheimer's disease, the temporal cortex, was selected from different AD patients and control subjects, and an extensive statistical analysis was employed. The temporal lobe was chosen since it is the most affected region in terms of AD pathological hallmarks ($A\beta$ and τ -tangles), as mentioned earlier. In order to investigate different iron forms on the same sample, experiments were performed by different techniques, which required the use of formalin-fixed tissue (see Materials and Methods).

In the following discussion, we first analyse each iron form separately, and then summarize the statistically relevant conclusions which we divide into correlations common to both groups, and differences between groups. Additionally, we compare these findings with MRI R_2^* values obtained from the very same anatomical region.

The $g' = 4.3$ EPR band was found in every measured sample. This signal has been often ascribed in literature to non-heme high-spin Fe(III) in a system of rhombic symmetry^{57,58}. We exclude the possibility that this signal is due to sample environment contamination since it was absent when either the empty cavity or a test tube containing the fixating solution were studied. The signal can be ascribed to the $m_s = \pm 3/2$ Kramers doublet of rhombic $S = 5/2$ systems and it is not fully understood⁵⁹. This iron form has taken different names in the literature, including mono-nuclear "spurious" iron, labile iron, iron bound to complexes of low molecular weight, and non-transferrin bound iron (NTBI)^{1,60}. It is beyond the scope of this work to identify the specific ligand environment responsible for the observed signal. However, in our previous work, we already discussed why this signal is not ascribable to transferrin⁴⁰, the main iron transporter protein⁶¹.

The concentration of Fe(III) in the temporal cortex found in this study ranged between 1.58 and 14.95 $\mu\text{g/g}$ (wet weight), equivalent to 28.3 μM and 267.6 μM respectively, while the concentration of intracellular labile iron pool should fall in the 0.2–10 μM range, as assessed by several studies, which used EPR or fluorescent probes to quantify labile iron in homogenized tissue, cells, and ferritin solution^{62–66}. A quantitative comparison between the iron concentration obtained in our study versus the commonly accepted values suggests that our $g' = 4.3$ band cannot *exclusively* be attributed to the labile iron pool. On the other hand, here we speculate that the signal can originate from a site that is part of the ferritin iron core, but does not show superparamagnetic properties. Indeed, this signal is often found in studies of the incorporation of iron into mammalian and bacterial ferritins^{67,68}. Additionally, from a magnetic viewpoint, this iron could be present on the outer surface of the core, thus experiencing a smaller Weiss molecular field than those atoms strongly bound to the core. This may result in a lower Néel temperature, as already proposed⁶⁹, and the effective paramagnetic behaviour demonstrable by the $g' = 4.3$ signal⁴⁰.

The ferrihydrite concentrations assayed in the present study (range: 25.8–730.7 $\mu\text{g/g}$) are in agreement with those reported earlier for ferritin¹⁸. Ferrihydrite concentration provides a measure of the ferritin-bound iron in




Figure 2. Visual representation of the iron forms grouped by Braak Stage. Each plot represents the concentration/magnetic property of the different iron forms grouped by the Braak Stage-number (outliers have been removed). All controls with Braak Stage equal to 3 or lower have been grouped in the variable “Braak Stage 3”. The AD patients have Braak Stage varying from 4 to 6. The μ symbol refers to the magnetic moment of the magnetite particle. For missing data in the ‘Magnetite μ ’ variable, please see Materials and Methods.




Figure 3. Correlogram of the iron forms measured in this study and grouped by diagnosis. The ellipse eccentricity and color intensity are proportional to the Spearman's correlation coefficient for a specific pair of iron forms (see also scale bar at the bottom). Left panel refers to the control group ($N = 11$, after outliers were removed as explained in the Materials and Methods section) while the right panel refers to the patients group ($N = 18$, after outlier removal). Correlograms which are not statistically significant, i.e. p -value > 0.05 , are crossed. For those correlograms with p -value < 0.05 , the correlation coefficient is reported in the respective squares. Letters are used to facilitate the comparison between pairs of variables.

the tissue, while its magnetic moment is related to the iron loading of the protein. Typically, 4500 iron atoms per protein are considered to be the maximum which the core can store *in vitro*. However, *in vivo* loading may be lower: some studies reported a loading of 1500 atoms *in vivo*^{70,71}, corresponding to roughly 33% of the protein capacity. Other findings show that, when ferritin is fractionated by density gradient centrifugation, the full range

	Fe(III)	Ferrihydrite	FLR
Fe(III)	1	-0.033	0.700
p-value	0	0.852	$3.453 \cdot 10^{-5}$ (***)
Ferrihydrite		1	-0.464
p-value		0	$1.279 \cdot 10^{-2}$ (*)
FLR			1
p-value			0

Table 2. Result of the partial correlation test. The partial correlation coefficient is reported together with the p-value of the test. AD and control groups have been pooled. The asterisk (*) indicates that the p-value is less than 0.05 while the triple asterisk (***) indicates that $p < 0.001$.

of ferritins, from native apoferritin to full ferritin, is found^{72,73}. Our control subjects display an FLR $\leq 50\%$ (the percentage refers to a maximum loading of 4500 atoms), while the AD patients display larger ferritin filling ratios, although this difference is not statistically significant.

Another mineralized iron form we were able to detect is magnetite/maghemite. Our IRM measurements are not able to disentangle magnetite and its oxidation product, maghemite. The concentration of magnetite/maghemite assayed (range: 0–418.4 ng/g) and the particles' size that we previously estimated⁴⁰ are within the range reported by others for magnetite in the frontal and temporal lobe^{15,16}, although here we are sensitive to larger particles than in previous studies (see Materials and Methods). The magnetic moment (μ) of these particles is a measure of their volume. We point out that, given the large magnetic moment associated with these particles, i.e. larger than $100 \mu_B$ for ferrihydrite and $1000 \mu_B$ for magnetite/maghemite, this study suggests that MRI could be employed to selectively identify them in the brain of patients with AD.

In the following, we discuss the differences in the above-described iron forms between AD and control subjects. From Fig. 4, we observe that ferrihydrite levels, magnetite/maghemite magnetic moment and R_2^* values are elevated in the temporal cortex of AD patients. The same iron forms show a positive trend with the Braak Stage (Fig. 2), which describes the distribution pattern of neurofibrillary changes⁷⁴ and reflects the clinical progression of AD. This is in agreement with the work of Van Duijn *et al.*, who recently showed a correlation between iron accumulation in the frontal cortex, the amount of $A\beta$ and τ pathology⁴¹ and the Braak Stage.

The increase of ferrihydrite levels in the absence of an increase in the average FLR confirms earlier studies, suggesting a local accumulation of iron in the brain of AD patients² and a higher expression of ferritin protein⁷¹. Given the recent observation that ferritin levels in the cerebrospinal fluid and in the plasma are associated with cognitive impairment progression in AD and with amyloid burden^{75,76}, and given the results of the present study, we believe that more investigations on the role of ferritin in AD progression are needed.

We did not find higher concentrations of magnetite/maghemite in the brain region investigated by us (middle temporal lobe). However, we did observe larger magnetic moments which suggest that magnetite/maghemite particles found in the AD tissue are larger than those found in controls (see Fig. 4). To explain higher magnetite levels, it was hypothesized that biogenic magnetite could originate from malfunctioning ferritin^{9,14,16}, and more recently, $A\beta$ was shown to mediate the formation of magnetite from ferrihydrite *in vitro*¹⁰. However, a few recent studies show that $A\beta$ is able to catalyse magnetite formation, even in absence of ferritin, under non-physiological pH conditions⁷⁷. Additionally, Maher *et al.*⁷⁸ reported that some of these magnetite particles, which were found in the frontal cortex, had a characteristic spherical, rather than cubic, geometry and shared a striking resemblance to anthropogenic, combustion-derived magnetite nanoparticles. Leaving aside the origin of these anthropogenic/biogenic nanoparticles, our results suggest that the size of these magnetite particles is different in presence of AD when compared to the control case.

The elevated R_2^* values in the AD subjects could be caused by an increase of cortical iron, as suggested by previous *ex vivo*⁷⁹ and *in vivo*⁸⁰ observations, where cortical tissue was studied with the same R_2^* -weighted pulse sequence. Indeed, QSM suggests that an increase in the susceptibility of the neocortex is associated with local iron accumulation^{28,81,82}, possibly increasing with the disease staging. Additionally, a significant correlation was found between MRI pixel intensity, iron and myelin²⁵. However in the present study, we did not observe a correlation between the R_2^* values and any assessed iron form. This may be due to the small dynamic range of iron concentration within the temporal cortex, which can affect the Spearman's correlation coefficient, or to the difference in the spatial resolution of the different techniques (see Materials and Methods). An R_2^* increase may also originate from susceptibility changes occurring in tissue lesions, i.e. $A\beta$ and τ -tangles⁸³, as pointed out by the trend between R_2^* and Braak Stage shown in Fig. 2, or be caused by microhemorrhages, or myelin changes^{36,38} also taking place in AD²⁵.

Finally, our correlation study (see Table 2) indicates that the Fe(III)-form quantified by EPR is not 'unspecific', but it is most likely associated with the iron loading of ferritin. This finding suggests that the EPR-detected iron could originate from the iron pool on the outer-surface of the ferrihydrite mineral, as suggested above. Additionally, the surprising negative correlation between ferrihydrite concentration and the FLR may be understood in a scenario in which, when the cytoplasmic iron pool increases, ferritin over-expression is initiated as a protective mechanism⁶. This can start a process in which iron is rapidly taken up by newly expressed ferritins, thus resulting in a heterogeneous FLR, and in ferritins which are on average less-filled than those found




Figure 4. Violin plots of the measured iron forms and their magnetic properties. Experimental data, i.e. iron form concentrations and magnetic moment, grouped by diagnosis (AD and control). Each plot shows individual data (black dots), the mean (red dot) and the histogram of the data (curve line). The number on top of the data is the p-value obtained from the Student's t-test performed on the two groups. “Significant” indicates a p-value less than 0.05. The top row represents the iron forms and property showing a not significant result, while the bottom row represents the significantly different iron forms. The double asterisk (**) signifies that the p-value is less than 0.01.

under normal iron levels. Ultimately, the moderate correlation between magnetite/maghemite and ferrihydrite is intriguing and deserves future investigation.

In this work, the temporal cortex of AD patients ($N = 22$) and control subjects ($N = 14$) was investigated to study the different molecular forms and magnetic properties of iron. An indirect assessment of the iron concentration was performed by measuring the R_2^* in the gray matter. The same region was also investigated by EPR and SQUID magnetometry and the concentration of non-heme rhombic Fe(III), magnetite/maghemite and ferrihydrite, and their respective magnetic moments were derived. Statistical analysis revealed that R_2^* values, ferrihydrite levels, and magnetite/maghemite magnetic moment are elevated in the temporal cortex of AD patients. This suggests a local accumulation of iron and an interaction between magnetite and, possibly $A\beta$ *in vivo*, in agreement with previous studies.

The correlation study of the measured iron forms indicates that Fe(III) strongly correlates with the amount of iron stored within ferritin, and the negative associations between ferrihydrite and the FLR could be interpreted as a result of heterogeneously-loaded ferritins, possibly due to ferritin over-expression, to cope with iron overload.

References

1. Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R. & Zecca, L. The role of iron in brain ageing and neurodegenerative disorders. *The Lancet Neurology* **13**, 1045–1060 (2014).
2. Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R. & Crichton, R. R. *Nature Reviews Neuroscience* **5**, 863–873 (2004).
3. Bishop, G. M. *et al.* Iron A pathological mediator of Alzheimer disease? *Developmental Neuroscience* **24**, 184–187 (2002).
4. Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P. & Youdim, M. B. H. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. *Journal of Neural Transmission - Parkinson's Disease and Dementia Section* **2**, 327–340 (1990).
5. Connor, J. R., Snyder, B. S., Beard, J. L., Fine, R. E. & Mufson, E. J. Regional Distribution of Iron and Iron-Regulatory Proteins in the Brain in Aging and Alzheimers-Disease. *Journal of Neuroscience Research* **31**, 327–335 (1992).
6. Roberts, B. R., Ryan, T. M., Bush, A. I., Masters, C. L. & Duce, J. A. The role of metallobiology and amyloid- β peptides in Alzheimer's disease. *Journal of Neurochemistry* **120**, 149–166 (2012).
7. Tao, Y., Wang, Y., Rogers, J. T. & Wang, F. Perturbed iron distribution in Alzheimer's disease serum, cerebrospinal fluid, and selected brain regions: A systematic review and meta-analysis. *Journal of Alzheimer's Disease* **42**, 679–690 (2014).
8. Hare, D. J. *et al.* Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in alzheimer's disease frontal cortex. *NeuroImage* **137**, 124–131 (2016).
9. Collingwood, J. F. *et al.* Three-dimensional tomographic imaging and characterization of iron compounds within alzheimer's plaque core material. *J. Alzheimers Dis.* **14**, 235–245 (2008).
10. Everett, J. *et al.* Evidence of redox-active iron formation following aggregation of ferrihydrite and the alzheimer's disease peptide β -amyloid. *Inorganic Chemistry* **53**, 2803–2809 (2014).
11. Everett, J. *et al.* Ferrous iron formation following the co-aggregation of ferric iron and the alzheimer's disease peptide β -amyloid (1–42). *Journal of The Royal Society Interface* **11** (2014).

12. Quintana, C., Cowley, J. & Marhic, C. Electron nanodiffraction and high-resolution electron microscopy studies of the structure and composition of physiological and pathological ferritin. *Journal of Structural Biology* **147**, 166–178 (2004).
13. Quintana, C. *et al.* Study of the localization of iron, ferritin, and hemosiderin in alzheimer's disease hippocampus by analytical microscopy at the subcellular level. *Journal of Structural Biology* **153**, 42–54 (2006).
14. Dobson, J. Nanoscale biogenic iron oxides and neurodegenerative disease. *FEBS Letters* **496**, 1–5 (2001).
15. Kirschvink, J. L., Kobayashi-Kirschvink, A. & Woodford, B. J. Magnetite biomineralization in the human brain. *Proceedings of the National Academy of Sciences of the United States of America* **89**, 7683–7687 (1992).
16. Pankhurst, Q., Hautot, D., Khan, N. & Dobson, J. Increased levels of magnetic iron compounds in alzheimer's disease. *Journal of Alzheimer's Disease* **13**, 49–52 (2008).
17. Goya, G. F., Berquó, T. S., Fonseca, F. C. & Morales, M. P. Static and dynamic magnetic properties of spherical magnetite nanoparticles. *Journal of Applied Physics* **94**, 3520 (2003).
18. Haacke, E. M. *et al.* Imaging iron stores in the brain using magnetic resonance imaging. *Magnetic Resonance Imaging* **23**, 1–25 (2005).
19. van Rooden, S. *et al.* 7T T2*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. *Neurobiology of Aging* **36**, 20–26 (2015).
20. Schenck, J. F. & Zimmerman, E. A. High-field magnetic resonance imaging of brain iron: Birth of a biomarker? *NMR in Biomedicine* **17**, 433–445 (2004).
21. Chavhan, G. B., Babyn, P. S., Thomas, B., Shroff, M. M. & Haacke, E. M. Principles, Techniques, and Applications of T2*-based MR Imaging and Its Special Applications. *RadioGraphics- Education Exhibit* **29**, 1433–1449 (2009).
22. Gossuin, Y., Gillis, P., Hocq, A., Vuong, Q. L. & Roch, A. Magnetic resonance relaxation properties of superparamagnetic particles. *Nanomedicine and nanobiotechnology* **1**, 299–310 (2009).
23. Gossuin, Y., Roch, A., Muller, R. N. & Gillis, P. Relaxation induced by ferritin and ferritin-like magnetic particles: The role of proton exchange. *Magnetic Resonance in Medicine* **43**, 237–243 (2000).
24. Nabuurs, R. J. A. *et al.* High-field mri of single histological slices using an inductively coupled, self-resonant microcoil: application to *ex vivo* samples of patients with alzheimer's disease. *NMR in Biomedicine* **24**, 351–357 (2011).
25. Bulck, M. *et al.* Post-mortem MRI and histology demonstrate differential iron accumulation and cortical myelin organization in early and late onset Alzheimer's disease. *Neurobiology of Aging* (2017).
26. Vymazal, J., Zak, O., Bulte, J. W. M., Aisen, P. & Brooks, R. A. T1 and T2 of ferritin solutions: Effect of loading factor. *Magnetic Resonance in Medicine* **36**, 61–65 (1996).
27. Bartzokis, G., Aravagiri, M., Oldendorf, W. H., Mintz, J. & Marder, S. R. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. *Magnetic resonance in medicine* **29**, 459–64 (1993).
28. Acosta-Cabronero, J., Betts, M. J., Cardenas-Blanco, A., Yang, S. & Nestor, P. J. *In Vivo* MRI Mapping of Brain Iron Deposition across the Adult Lifespan. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **36**, 364–74 (2016).
29. Haacke, E. M. *et al.* Quantitative susceptibility mapping: Current status and future directions. *Magnetic Resonance Imaging* **33**, 1–25 (2015).
30. Yao, B. *et al.* Susceptibility contrast in high field MRI of human brain as a function of tissue iron content. *NeuroImage* **44**, 1259–1266 (2009).
31. Xu, X., Wang, Q. & Zhang, M. Age, gender, and hemispheric differences in iron deposition in the human brain: An *in vivo* mri study. *NeuroImage* **40**, 35–42 (2008).
32. Bartzokis, G. *et al.* Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. *Neurobiology of Aging* **28**, 414–423 (2007).
33. Brooks, R. a., Moiny, F. & Gillis, P. On T2 -Shortening by Weakly Magnetized Particles: The Chemical Exchange Model-comparison **45**, 1014–1020 (2001).
34. Bizzi, A. *et al.* Role of iron and ferritin in MR imaging of the brain: a study in primates at different field strengths. *Radiology* **177**, 59–65 (1990).
35. Hocq, A. *et al.* Variable-field relaxometry of iron-containing human tissues: A preliminary study. *Contrast Media and Molecular Imaging* **4**, 157–164 (2009).
36. Stüber, C. *et al.* Myelin and iron concentration in the human brain: A quantitative study of MRI contrast. *NeuroImage* **93**, 95–106 (2014).
37. Brem, F., Tiefenauer, L., Fink, A., Dobson, J. & Hirt, A. M. A mixture of ferritin and magnetite nanoparticles mimics the magnetic properties of human brain tissue. *Phys. Rev. B* **73**, 224427 (2006).
38. Li, T.-Q. *et al.* Characterization of T(2)* heterogeneity in human brain white matter. *Magnetic Resonance in Medicine* **62**, 1652–7 (2009).
39. Meadowcroft, M. D., Peters, D. G., Dewal, R. P., Connor, J. R. & Yang, Q. X. The effect of iron in mri and transverse relaxation of amyloid-beta plaques in alzheimer's disease. *NMR in Biomedicine* **28**, 297–305 (2015).
40. Kumar, P. *et al.* A novel approach to quantify different iron forms in *ex-vivo* human brain tissue. *Scientific Reports* **6**, 1–13 (2016).
41. van Duijn, S. *et al.* Cortical Iron Reflects Severity of Alzheimer's Disease. *Journal of Alzheimer's Disease* **1–13** (2017).
42. Stoll, S. & Schweiger, A. Easyspin, a comprehensive software package for spectral simulation and analysis in epr. *Journal of Magnetic Resonance* **178**, 42–55 <http://www.sciencedirect.com/science/article/pii/S1090780705002892> (2006).
43. Makhlof, S. A., Parker, F. T. & Berkowitz, A. E. Magnetic hysteresis anomalies in ferritin. *Physical Review B* **55**, R14717–R14720 (1997).
44. Brem, F., Stamm, G. & Hirt, A. M. Modeling the magnetic behavior of horse spleen ferritin with a two-phase core structure. *Journal of Applied Physics* **99**, 123906 (2006).
45. Cullity, B. D. & Graham, C. D. *Introduction to magnetic materials*, vol. 12 (2009).
46. Dar, M. I. & Shivashankar, S. A. Single crystalline magnetite, maghemite, and hematite nanoparticles with rich coercivity. *RSC Advances* **4**, 4105–4113 (2014).
47. Zergenyi, R. S., Hirt, A. M., Zimmermann, S., Dobson, J. P. & Lowrie, W. Low-temperature magnetic behavior of ferrihydrite. *Journal of Geophysical Research* **105**, 8297–8303 (1999).
48. Harris, J. G. E., Grimaldi, J. E., Awschalom, D. D., Chioloro, A. & Loss, D. Excess Spin and the Dynamics of Antiferromagnetic Ferritin. *Physical Review B* **60**, 4 (1999).
49. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*. (Springer-Verlag, New York, 2009). <http://ggplot2.org>.
50. Schloerke, B. *et al.* ggobi/ggally: Ggally 1.3.0. <https://doi.org/10.5281/zenodo.166547> (2016).
51. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria <http://www.R-project.org/> (2013).
52. Komsta, L. *Outliers: Tests for outliers*. R package version 0.14. <https://CRAN.R-project.org/package=outliers> (2011).
53. Wei, T. & Simko, V. *R package "corrplot": Visualization of a Correlation Matrix* (Version 0.84). <https://github.com/taiyun/corrplot> (2017).
54. Kim, S. Ppcor: An r package for a fast calculation to semi-partial correlation coefficients. *Communications for Statistical Applications and Methods* **22**, 665–674 (2015).
55. Field, A. *Discovering Statistics Using SPSS* (SAGE Publications, 2009).

56. Hare, D. J., Gerlach, M. & Riederer, P. Considerations for measuring iron in post-mortem tissue of Parkinson's disease patients. *Journal of Neural Transmission* **119**, 1515–1521 (2012).
57. Krzyminiowski, R. *et al.* EPR Study of Iron Ion Complexes in Human Blood. *Applied magnetic resonance* **40**, 321–330 (2011).
58. Cammack, R. & Cooper, C. E. Electron paramagnetic resonance spectroscopy of iron complexes and iron-containing proteins. *Methods in Enzymology* **227**, 353 (1993).
59. Carrette, N. *et al.* Optical and epr spectroscopic studies of demetallation of hemin by l-chain apoferritins. *Journal of Inorganic Biochemistry* **100**, 1426–1435 (2006).
60. Bou-Abdallah, F. & Chasteen, N. D. Spin concentration measurements of high-spin ($g = 4.3$) rhombic iron (iii) ions in biological samples: theory and application. *Journal of Biological Inorganic Chemistry* **13**, 15–24 (2007).
61. Duck, K. A. & Connor, J. R. Iron uptake and transport across physiological barriers. *BioMetals* **29**, 573–591 (2016).
62. Moser, J. C. *et al.* Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer. *Redox Biology* **2**, 22–27 (2014).
63. Ma, Y., de Groot, H., Liu, Z., Hider, R. C. & Petrat, F. Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probes. *The Biochemical journal* **395**, 49–55 (2006).
64. Lipiński, P. *et al.* Intracellular iron status as a hallmark of mammalian cell susceptibility to oxidative stress: a study of L5178Y mouse lymphoma cell lines differentially sensitive to H₂O₂. *Blood* **95**, 2960–6 (2000).
65. Breuer, W., Epsztejn, S. & Cabantchik, Z. I. Dynamics of the cytosolic chelatable iron pool of K562 cells. *FEBS Letters* **382**, 304–308 (1996).
66. Kruszewski, M. Labile iron pool: The main determinant of cellular response to oxidative stress. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis* **531**, 81–92 (2003).
67. Sun, S. J. & Chasteen, N. D. Rapid Kinetics of the Epr-Active Species Formed During Initial Iron Uptake in Horse Spleen Apoferritin. *Biochemistry* **33**, 15095–15102 (1994).
68. Chasteen, N. D., Antanaitstll, C. & Aisenqll, P. Iron Deposition in Apoferritin. *Journal of Biological Chemistry* **260**, 2926–2929 (1985).
69. Brooks, R. A., Vymazal, J., Goldfarb, R. B., Bulte, J. W. M. & Aisen, P. Relaxometry and Magnetometry of Ferritin. *Magnetic Resonance in Medicine* **227–235** (1998).
70. Kell, D. B. & Pretorius, E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. *Metallomics* **6**, 748 (2014).
71. Dedman, D. J. *et al.* Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. *The Biochemical journal* **287**(Pt 2), 509–14 (1992).
72. Stuhmann, H. B., Haas, J., Ibel, K., Koch, M. H. & Crichton, R. R. Low angle neutron scattering of ferritin studied by contrast variation. *Journal of Molecular Biology* **100**, 399–413 (1976).
73. Fischbach, F. A. & Anderegg, J. W. An X-ray scattering study of ferritin and apoferritin. *Journal of Molecular Biology* **14**, IN15–473 (1965).
74. Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* **82**, 239–259 (1991).
75. Ayton, S. *et al.* Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. *Nature Communications* **6**, 6760 (2015).
76. Goozee, K. *et al.* Elevated plasma ferritin in elderly individuals with high neocortical amyloid- β load. *Molecular Psychiatry* **1–6** (2017).
77. Tahirbegi, I. B., Pardo, W. A., Alvira, M., Mir, M. & Samitier, J. Amyloid $\alpha\beta_{42}$, a promoter of magnetite nanoparticle formation in alzheimer's disease. *Nanotechnology* **27**, 465102 (2016).
78. Maher, B. A. *et al.* Magnetite pollution nanoparticles in the human brain. *Proceedings of the National Academy of Sciences of the United States of America* **113**, 10797–801 (2016).
79. van Rooden, S. *et al.* Cerebral amyloidosis: Postmortem detection with human 7.0-t mr imaging system. *Radiology* **253**, 788–796 (2009).
80. van Rooden, S. *et al.* Cortical phase changes in alzheimer's disease at 7t mri: A novel imaging marker. *Alzheimer's & dementia: the journal of the Alzheimer's Association* **10**, e19–26 (2014).
81. van Bergen, J. M. G. *et al.* Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment. *Scientific Reports* **6**, 35514 (2016).
82. Sun, H. *et al.* Validation of quantitative susceptibility mapping with Perls' iron staining for subcortical gray matter. *NeuroImage* **105**, 486–492 (2015).
83. Nabuurs, R. J. *et al.* MR microscopy of human amyloid- β deposits: Characterization of parenchymal amyloid, diffuse plaques, and vascular amyloid. *Journal of Alzheimer's Disease* **34**, 1037–1049 (2013).

Acknowledgements

We are grateful to Marc Derieppe for helping with the Matlab code, C. Koeleman for technical assistance during tissue freeze-drying, and J. Aarts for access to the SQUID magnetometer. G. Kracht is thanked for revising the figures. This work was supported by the Dutch Foundation for Fundamental Research on Matter (FOM), by the Netherlands Organization for Scientific Research (NWO) through a VICI fellowship to T. H. O., and through a VENI fellowship to L. B (016.Veni.188.040). One of us (M. B.) was supported by the FP7 European Union Marie Curie IAPP Program, BRAINPATH, under grant number 612360. Partial funding was provided by European Research Council, Advanced Grant 670629 NOMA MRI. N.L. acknowledges support from the research program DESCO, which is financed by the Netherlands Organisation for Scientific Research (NWO).

Author Contributions

L.B., T.H.O., M.H., A.W. and L.v.d.W. conceived the experiments. L.B., W.B., M.B. and M.H. conducted the experiments. L.B., W.B. and M.B. analysed the results. N.L. provided support during the SQUID magnetometry experiments. J.G. provided the expertise on statistics. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-018-25021-7>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018